233 related articles for article (PubMed ID: 26952044)
1. Carfilzomib reverses pulmonary arterial hypertension.
Wang X; Ibrahim YF; Das D; Zungu-Edmondson M; Shults NV; Suzuki YJ
Cardiovasc Res; 2016 May; 110(2):188-99. PubMed ID: 26952044
[TBL] [Abstract][Full Text] [Related]
2. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
3. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
5. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
6. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
7. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
[TBL] [Abstract][Full Text] [Related]
8. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing.
Ibrahim YF; Wong CM; Pavlickova L; Liu L; Trasar L; Bansal G; Suzuki YJ
J Am Heart Assoc; 2014 Feb; 3(1):e000520. PubMed ID: 24572252
[TBL] [Abstract][Full Text] [Related]
10. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.
Fan YF; Zhang R; Jiang X; Wen L; Wu DC; Liu D; Yuan P; Wang YL; Jing ZC
Cardiovasc Res; 2013 Aug; 99(3):395-403. PubMed ID: 23650288
[TBL] [Abstract][Full Text] [Related]
11. Quercetin reverses experimental pulmonary arterial hypertension by modulating the TrkA pathway.
He Y; Cao X; Liu X; Li X; Xu Y; Liu J; Shi J
Exp Cell Res; 2015 Nov; 339(1):122-34. PubMed ID: 26476374
[TBL] [Abstract][Full Text] [Related]
12. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
13. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
Huh JW; Kim SY; Lee JH; Lee YS
Pulm Pharmacol Ther; 2011 Dec; 24(6):638-46. PubMed ID: 21963997
[TBL] [Abstract][Full Text] [Related]
14. Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.
Chen-Scarabelli C; Corsetti G; Pasini E; Dioguardi FS; Sahni G; Narula J; Gavazzoni M; Patel H; Saravolatz L; Knight R; Raddino R; Scarabelli TM
EBioMedicine; 2017 Jul; 21():206-212. PubMed ID: 28587834
[TBL] [Abstract][Full Text] [Related]
15. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH.
Courboulin A; Barrier M; Perreault T; Bonnet P; Tremblay VL; Paulin R; Tremblay E; Lambert C; Jacob MH; Bonnet SN; Provencher S; Bonnet S
Eur Respir J; 2012 Sep; 40(3):618-29. PubMed ID: 22496325
[TBL] [Abstract][Full Text] [Related]
16. A possible antineoplastic potential of selective, irreversible proteasome inhibitor, carfilzomib on chemically induced hepatocarcinogenesis in rats.
Mansour MA; Aljoufi MA; Al-Hosaini K; Al-Rikabi AC; Nagi MN
J Biochem Mol Toxicol; 2014 Sep; 28(9):400-6. PubMed ID: 24861196
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib alleviates experimental pulmonary arterial hypertension.
Kim SY; Lee JH; Huh JW; Kim HJ; Park MK; Ro JY; Oh YM; Lee SD; Lee YS
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):698-708. PubMed ID: 22842494
[TBL] [Abstract][Full Text] [Related]
18. Modulators of right ventricular apoptosis and contractility in a rat model of pulmonary hypertension.
Zungu-Edmondson M; Shults NV; Wong CM; Suzuki YJ
Cardiovasc Res; 2016 May; 110(1):30-9. PubMed ID: 26790474
[TBL] [Abstract][Full Text] [Related]
19. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel Reverses Pulmonary Vascular Remodeling by Decreasing Autophagy and Resolves Right Ventricular Fibrosis.
Ibrahim YF; Shults NV; Rybka V; Suzuki YJ
J Pharmacol Exp Ther; 2017 Oct; 363(1):20-34. PubMed ID: 28760737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
